CT引导下放射性125I粒子植入治疗合并癌痛难治性恶性肿瘤的疗效观察

Observation on the Efficacy of Radioactive 125I Seed Implantation Guided by CT in the Treatment of Refractory Malignant Tumors Complicated with Cancer Pain

目的:探索CT引导下放射性125I粒子植入疗法在伴有癌痛的难治性恶性肿瘤患者中的疗法。方法:纳入2017年3月~2018年12月本院肿瘤内科诊治的伴有癌痛的难治性恶性肿瘤患者156例为观察对象,全部患者均在CT引导下植入放射性125I粒子,收集患者治疗前后的疼痛评分、近期疗效等。结果:治疗24h、3d、4周、12周后的疼痛评分较治疗前均明显降低,P<0.001;其中在治疗3d后VAS评分降至最低,后略有升高。本组156例患者近期有效率50.64%,临床获益率80.77%;术后不良反应发生率3.85%,未出现严重不良反应;随访6个月生存率为94.87%,1年生存率84.62%。结论:CT引导下放射性125I粒子植入术在伴有癌痛的难治性恶性肿瘤患者治疗中应用利于促进癌痛症状缓解,促进肿瘤控制,且安全性高,近远期疗效显著。

Objective:To explore the treatment of CT-guided radioactive 125I seed implantation in patients with refractory malignant tumors with cancer pain.Methods:156 patients with refractory malignant tumors with cancer pain who were diagnosed and treated in the Department of Oncology of our hospital from March 2017 to December 2018 were included as observation objects.All patients were implanted with radioactive 125I seeds under the guidance of CT,and the patients were collected pain score before and after treatment,short-term efficacy,etc.Results:The pain scores of 24 hours,3 days,4 weeks and 12 weeks after treatment were significantly lower than those before treatment(P<0.001),and the VAS score decreased after 3 days of treatment.To the lowest,after a slight increase.The shortterm effective rate was 50.64%,the clinical benefit rate was 80.77%,the incidence of postoperative adverse reactions was 3.85%,and no serious adverse reactions occurred.The 6-month survival rate was 94.87%and the 1-year survival rate was 84.62%.Conclusion:The application of radioactive 125I seed implantation guided by CT in the treatment of refractory malignant tumors with cancer pain is beneficial to promote the relief of cancer pain symptoms and tumor control,and the shortterm and long-term curative effect is remarkable.